This invention relates to medical devices, more particularly to vessel closure members, delivery apparatuses, and methods of inserting the closure members.
Open surgical procedures which require incisions through skin, tissue, and organs have a traumatic effect on the body and can lead to substantial blood loss. In addition, such procedures expose tissue and organs to the outside environment which creates an increased risk of post-operative infection. After open surgical procedures, patients are generally in pain, require substantial recovery time, and are susceptible to post-operative complications. As a result, open surgical procedures are generally higher in cost and have a higher degree of risk.
Because of the problems associated with open surgical procedures, the use of minimally invasive surgically techniques has grown substantially over the recent years. As these techniques have developed, the number and types of treatment devices, including vessel closure members, have proliferated. Vessel closure members are generally used for sealing fluid passageways in patients, including but not limited to, percutaneous sites in femoral arteries or veins resulting from intravascular procedures, cardiovascular deformations, fallopian tubes and the vas deferens to prevent conception, and vessels in the brain. Recently, much focus has been placed on developing closure members which allow quicker hemostasis during intravascular procedures and closure members which quickly and effectively occlude fallopian tubes or the vas deferens to prevent conception.
One of the important benefits of minimally invasive intravascular procedures is less patient blood loss; however, particularly in procedures in which the femoral artery is accessed, achieving quick and effective hemostasis at the puncture site still can be problematic. More recently, the increased use of heparin and larger sized introducer sheaths have presented additional challenges. When larger devices are introduced into a artery or vein, e.g., 5 Fr or larger, external manual or mechanical compression applied at the entry site, commonly the femoral artery or vein, has been the standard method of achieving hemostasis, which occurs when a thrombus forms at the vessel opening, thereby preventing further bleeding at the site. External compression typically requires that the constant, firm pressure is maintained for up to 30 minutes until hemostasis has been achieved. Even after hemostasis, the site remains vulnerable to further bleeding, especially if the patient is moved.
To address the obvious inadequacies of using manual or external compression alone to close a percutaneous site, a number of devices have been developed to assist in closure of the entry site. Various suturing devices have developed by Perclose, Inc. and sold by Abbott Laboratories (Redwood City, Calif.) that deliver needles that penetrate the arterial wall to form a knot to close the puncture site. While suturing produces relatively quick and reliable hemostasis when compared to external compression, it is a technique that requires much skill and experience on the part of the physician. In addition, the complexity of the device has led to reports of failures such as in the ability to form a proper knot and other problems. Another known complication is when the device is deployed such that the needles penetrate completely through the opposite wall of the target vessel, which can inadvertently lead to the vessel being closed off, a potentially serious event for the patient.
Hemostatic collagen plugs offer a lower cost, simpler alternative to suturing devices and they have increased in popularity, particularly the VASOSEAL® (Datascope Corp., Montvale, N.J.) and ANGIOSEAL™ (The, Kendall Co., Mansfield Mass.) closure devices. VASOSEAL® comprises a bovine collagen sponge plug that is pushed through a blunt tract dilator through the tissue puncture channel where it is deployed against the outer vessel wall to seal the puncture site. The collagen plug swells with blood and helps occlude blood flow. Manual pressure is still required following initial hemostasis until thrombosis formation is sufficient. Complications can occur from the dilator entering the vessel where the collagen can be accidentally deployed. Placement of the device also requires that the depth of the tissue channel be pre-measured to achieve satisfactory placement. The ANGIOSEAL® device is similar except that it includes a prosthetic anchorplate that is left inside the vessel where it biodegrades in about 30 days. Re-puncture at the site can typically occur at that time at the site, but may be problematic if the anchor device has not been reabsorbed. Additionally both closure devices, being made of bovine collagen, can cause the formation of fibrotic tissue in some patients, which in severe cases, has been known to be sufficient to restrict blood flow within the vessel. A third device utilizing collagen is the DUETT™ sealing device (Vascular Solutions Inc., Minneapolis, Minn.), which comprises a balloon catheter that delivers a. collagen and thrombin solution to the puncture site, which causes fibrinogen formation that seals the puncture site. Generally, collagen plugs have been of limited use in closing larger punctures sites and are typically intended for procedures involving 5-8 Fr introducer sheaths. Even suturing devices are intended for closing puncture sites in the small to moderate range, although some physicians have reportedly been able to perform an additional series of steps to suture larger arterial puncture sites, adding to the time and complexity of the procedure.
Currently available methods for permanently occluding or closing fallopian tubes and the vas deferens to prevent conception include tubal ligations and vasectomies. Both of these procedures, however, are invasive, are not generally performed in the doctor's office, and can be expensive. Prior art methods of occluding the fallopian tubes include placing an elastomeric plug or other member in the is thumus or narrow most portion of the fallopian tubes. These elastomeric plugs or other members, however, often migrate in the fallopian tube or otherwise become dislodged allowing sperm to pass through the fallopian tube and fertilize an egg released by an ovary. Another prior art fallopian tube occlusion device is disclosed in Nikolchev et al., U.S. Pat. No. 6,176,240 B1. Nikolchev et al. discloses a metallic coil which is pre-shaped into multiple loops separated by straight sections or pre-shaped into a “flower coil.” The metallic coil is inserted into the fallopian tube in an elongated state and when deployed returns to the “flower coil” shape which has a larger diameter than the fallopian tube. The fallopian tube occlusion device of Nikolchev et al. is complicated requiring the metallic coil to be pre-formed into a flower shape which must have a diameter larger than the interior of the fallopian tube, or the device will not lodge in the fallopian tube.
What is needed is a simple to use, relatively inexpensive, closure member that can provide safe and efficient closure of both smaller and larger vessels, including femoral veins and arteries, fallopian tubes, and the vas deferens. Ideally, such a member should be compatible with other instrumentation used in the procedure, it should be highly biocompatible, and it should allow subsequent access at the entry site after a reasonable period of time without further complications. In addition, the closure member should be designed for use with a delivery system that allows precise placement without having to pre-measure the tissue channel leading to the vessel, permits the closure member to be reliably place in the desired location, and delivers the closure member easily and reliably in the vessel or against the vessel wall.
The foregoing problems are solved and a technical advance is achieved in an illustrative closure apparatus and delivery system for delivering a closure member, typically an absorbable member comprising an extracellular matrix, within a body lumen or cavity to substantially restrict or occlude passage of fluids or other bodily materials therethrough or thereinto. In a first embodiment of the invention, the closure apparatus comprises a construct adapted to function as a hemostatic member. The hemostatic member typically comprises a generally cylindrical shape construct that is highly expandable In volume when exposed to blood. In one embodiment, the hemostatic member includes a functional passageway that allows the closure member to be mounted over a medical device, such as a delivery catheter or wire guide, for delivery against a vessel puncture or into another vascular environment, such as to fill an aneurysm sac, to treat an AV, gastroenteric, or extravascular fistula, treat an arterial or venous malformation, or to occlude a vessel. As used herein, functional passageway is defined as any longitudinal pathway extending through, or substantially through the hemostatic member and through which a medical device, such as a catheter or wire, can pass, and which offers little or minimal resistance such that the structure of the material(s) of construction are not broken, torn, or otherwise disrupted. An example of a non-function pathway would be where a device is forced through a foam or sponge material where a passageway is not already substantially preformed such that the cells of the foam must be mechanically separated as the device is forced therethrough.
Besides open lumens, examples of functional pathways would including self-sealing membranes or valves, gel-like or sealant materials, and compressed, rolled or folded constructs which have natural spaces between layers through which a medical device could pass.
In a second aspect of the invention, the hemostatic member includes a first material, such as a foam material, which is capable of absorbing blood to expand several times (e.g., 6-10×) its diameter to cause hemostasis, and a second material, such as a sheet of a biomaterial, which provides structural integrity. In one embodiment used to close arterial or venous punctures made during common intravascular procedures, the hemostatic member comprises a sheet of an extracellular collagen matrix (ECM) such as small intestinal submucosa (SIS) which is rolled together with a SIS sponge material comprising lyophilized and comminuted SIS that has been formed into a thin layer and cross-linked using one of several known cross-linking agents. It is the highly-absorbent sponge material that provides most of the radial expansion of the hemostatic member. The sheet of SIS, when rolled into a generally cylindrical construct along with the adjacent sheet of sponge material, adds structural integrity to the construct, allowing it to be used to seal larger puncture channels, such as 9-16 Fr, which typically fall outside the capabilities of collagen foam plugs. This is due primarily to the fact that the harvested SIS sheet material generally maintains its structure much longer than the ground collagen or SIS sponge when wet. Collagen sponge plugs essentially liquefy when exposed to blood and although then are able to shorten the time of hemostasis in punctures involving introducers up to 8 Fr in diameter, they are not indicated for sealing larger puncture sites. The two rolled sheets of SIS are compressed into a cylindrical construct and placed over a delivery catheter. Ideally, the hemostatic member comprises no more than half the length of tissue tract, which typically measures 3-4 cm in an average patient. It is within the scope of the invention for hemostatic member to comprise only the second material, such as a tightly rolled SIS construct, or it could include only the first, foam or sponge-like material (e.g., lyophilized SIS). For example, treating lyophilized SIS with more effective cross-linking agents could yield a construct having increased structural integrity that is comparable to the illustrative hemostatic member that includes an SIS sheet. SIS and other ECM biomaterials provide a clinical advantage over biomaterials containing mammalian cells or cellular debris in that they can be processed to be both highly biocompatible and thus, much better tolerated than traditional collagen-based implants. SIS is known to have the ability to stimulate angiogenesis and tissue ingrowth to become completely remodeled as host tissue over time. The process of obtaining purified SIS is described in U.S. Pat. No. 6,206,931 to Cook et. al.
The hemostatic member delivery apparatus includes an introducer sheath, which may represent the same sheath that is initially used in the intravascular procedure, a pusher member to provide counter force to hold the hemostatic member in place while the sheath is being withdrawn, and a wire guide which extends through the lumen of the mounting catheter and provides an atraumatic distal tip within the vessel. One method of delivering the hemostatic member to externally seal a puncture site includes the steps of loading the hemostatic member subassembly (which also includes the mounting catheter, wire guide, and pusher member) into the introducer sheath while the sheath is within the vessel. A splittable cartridge can be used to temporarily constrain the hemostatic member to facilitate the loading process into the introducer sheath. The hemostatic member subassembly is configured to correspond to the length of the introducer sheath such that when it is fully advanced into the sheath, the hemostatic member is positioned near the distal end of the introducer member. The introducer sheath and hemostatic member subassembly are partially withdrawn from the vessel such that the blunt end of the introducer sheath is outside the vessel. The opening narrows as the elastic vessel walls retract after the introducer sheath is withdrawn such that re-advancement would cause the introducer sheath to abut the outside of the vessel or tunica vascularis about the puncture site. An optional side hole is located on the delivery catheter just distal to the distal end to the hemostatic member which can provide a positional indicator for the delivery subassembly. Blood flowing into the side hole and through the delivery catheter, can be observed by the operator as it flows into a side port catheter, indicating that the tip of the introducer sheath is still outside the vessel. To make it such that blood can only enter the lumen of the mounting catheter though the side hole, a section of the distal portion of the wire guide can be made larger to act as a seal against the distal end of the mounting catheter.
With the distal tip of the introducer sheath abutting the vessel, the hemostatic member is deployed. A splittable deployment guard placed between the hub of the introducer sheath and the pusher member can be used to prevent accidental premature deployment. Once it is removed, the introducer sheath can be partially withdrawn, while holding the, pusher member in position, to expose either a part or all of the hemostatic; member to blood and allow it to expand within the tissue tract. An optional second side hole may be formed within the region over which the hemostatic member is mounted. The wire guide can either be advanced to allow blood to flow into the lumen of the mounting catheter, or it can be withdrawn from the mounting catheter lumen to allow blood to flow through the second side hole. Deployment of the hemostatic member against the vessel is accomplished by partial withdrawal of the introducer sheath, while the pusher member is maintained in position for a few minutes until the hemostatic member has swelled to its fully expanded state and has stabilized. The delivery catheter is removed from the pathway of the hemostatic member which swells to quickly seal any lumen left by its withdrawal. The pusher member is removed with the introducer member after stabilization, and external or mechanical compression is applied at the site for the recommended period of time or until the physician feels it is no longer is necessary.
In another aspect of the invention, the distal end of the hemostatic member includes a plurality of slits, such as two slits dividing the hemostatic member lengthwise into quarters and which extend for about 25-30% of its length. Slitting the distal portion of hemostatic member allows the distal end to expand outward to facilitate the sealing process.
In still other aspects of the invention, the second (sheet) material of the hemostatic member includes a folded, rather than a rolled configuration, which unfolds as the hemostatic member radially expands within the tissue channel. The folds can include any number of configurations such as radially-arranged pleat or parallel folds with the foam sheet typically being interspersed between the folds.
In yet another aspect of the invention, the hemostatic member delivery apparatus can be adapted to introduce the hemostatic member into an aneurysm to prevent leakage around a stent graft. In one embodiment, the stent graft includes an open section through which an outer delivery catheter could be introduced that would provide a means to deliver the, hemostatic members to the aneurysm after the stent graft had been placed. Afterward, another section of the stent graft would be introduced through the original stent graft and positioned over the open section. A second option would be to include a sleeve or other type of valve in the graft material through which the delivery system could be introduced. The valve would then close to prevent leakage of blood. One example of a hemostatic member delivery system for treatment of an aneurysm would comprise a series of hemostatic members placed adjacently over a wire guide and loaded into a delivery catheter. A pusher member would then individually deploy the hemostatic members individually until the aneurysm is filled.
In another aspect of the invention, the hemostatic member and delivery system is adapted for delivery into an aneurysm, such as an abdominal aortic aneurysm, such that the delivery catheter is positioned outside of the graft prosthesis, between the graft and the vessel wall. The graft prosthesis is then deployed, leaving the catheter tip inside the excluded aneurysm. This takes advantage of the fact that the technique is already well known for placement of contrast media infusion catheters in this manner. Conveniently, the same catheter for infusion of contrast can be used for the delivery of the hemostatic members. Another advantage is that the graft prosthesis need not be modified to provide temporary access into the aneurysm so that the catheter, which would likely be the case if the hemostatic members are to be delivered from the inside of the graft prosthesis.
In another aspect of the present invention, the closure member is fallopian tube member which after insertion into a fallopian tube, occludes the tube and blocks sperm from contacting a released egg thereby preventing conception. In one embodiment, the fallopian tube member includes a loop-shaped metal frame, a first material, a radiopaque binding wire, and a second material, such as a sheet of biomaterial which adds structural integrity. The fist material may include, a sponge-like or foam material, which is capable of absorbing blood and fluid, a lyophilized sheet of SIS, or a sheet of air-dried SIS. The second material may be a sheet of SIS.
The fallopian tube member may formed around a delivery catheter with an outer wall, a distal end, and a lumen extending therethrough. Two openings are provided opposite each other in the distal end of the delivery catheter transverse to the lumen. The metal wire or frame is threaded through the first opening, the lumen, and exits the second opening. The metal wire is then formed into a loop-shaped frame. Thereafter, a guide wire catheter with a distal end and a lumen extending therethrough is advanced through the delivery catheter until the distal end of the guide wire catheter extends beyond the distal end of the delivery catheter and the loop-shaped metal frame. A first material, which may be sponge-like, is wrapped around the distal end of the guide wire catheter and then a radiopaque binding wire is wrapped around the loop-shaped frame and the first material. In one embodiment, a second sheet of material is then wrapped around the loop shaped frame, the first material, and the radiopaque binding wire. The ends of the loop-shaped frame are then trimmed flush with outer wall of the delivery catheter. The frame, as defined herein, may assume a multiplicity of configurations and may comprise more than one component. The primary function of the frame is to have a portion thereof be able to engage the walls of the vessel to anchor the fallopian tube member therein and/or to cause trauma to the walls to encourage migration of fibrocytes into the member material to encourage tissue ingrowth that allows the fallopian tube member to become a permanent occlusion to prevent the passage of gametes (eggs or sperm) or other material.
One method of delivering the fallopian tube member into a fallopian tube includes the steps of providing a uterine introducer catheter which is inserted transcervially through a uterus to the ostium. The delivery catheter and coaxial guide wire catheter with fallopian tube member formed thereon are then advanced through the uterine introducer catheter. Once the fallopian tube member is positioned, the guide wire catheter is withdrawn. As the guide wire catheter is withdrawn, the fallopian tube member is deployed. The delivery catheter and introducer catheter are then removed.
In one embodiment of the present invention, depicted in
The larger-diameter portion 34 of the wire guide 32 serves to provide a seal of the passage 36 of the delivery catheter 29 when it abuts the catheter's distal end 35, allowing the operator to control whether blood can flow into the passage 36. This can allow the delivery catheter 29 to include positional monitoring capabilities to indicate whether the hemostatic member 11 is in the vessel, or properly positioned outside the vessel. To accomplish this, a side hole 37 is positioned just distal the first end 15 of the hemostatic member 11 which allows blood in the vessel to communicate with the passage 36, which is otherwise sealed by the wire guide 32. It may also be used for the injection of contrast media or dye. If the operator detects blood flowing from a side port catheter 39 (
Another component of the hemostatic member delivery subassembly is a pusher member 28 which is disposed over the delivery catheter 29 to abut the hemostatic member 11. The function of the pusher member 28 is to provide a counter force sufficient to hold the hemostatic member 11 in position against the vessel during deployment and the initial stages following hemostasis. The illustrative pusher member typically has a diameter 6-12 Fr, depending on the size of the hemostatic member 11 and the accompanying introducer sheath, and can be made of a variety of polymers, such a polyurethane, polyethylene, etc. that yield good column strength while preferably, having some degree of lateral flexibility.
The illustrative hemostatic member subassembly includes one component, a loading cartridge 40, which is not part of the hemostatic member delivery apparatus 26 in its final, pre-deployment state. The loading cartridge, which in the example of
The basic procedure for delivering the hemostatic member 11 against the outside of the vessel wall 48 is shown in
While a hemostatic member 11 comprising the rolled configuration 17 depicted in
The inclusion of a functional pathway 14 that advantageously permits the hemostatic member 14 to be loaded over a delivery device, such as a catheter, wire guide, for delivery into or against the vessel is one aspect of the invention that can provide more precise and efficient delivery. Hemostatic devices, such as the embodiment of
In a second use of the hemostatic member 11 of the present invention, the hemostatic member delivery system 26 invention can be modified to deliver the hemostatic member through or around a stent or stent graft, such as graft to treat an abdominal aortic aneurysm (AAA), particularly to cause hemostasis within the aneurysm to help prevent an endoleak such as around the stent graft, through a collateral vessel and back through artery, through a hole in the graft material, or because the graft material is too porous. In one embodiment depicted in
In one embodiment of the hemostatic member delivery apparatus 26, depicted in
Another embodiment of the closure member of the present invention, depicted in
A delivery catheter 150 having an outer wall 152, a proximal end 154 end, a distal end 156, and a lumen 158 extending through the length of the catheter is provided. The delivery catheter may range in size, and in a preferred embodiment 5 Fr. Two openings 160 and 162 are formed opposite one another in the distal end 156 of the delivery catheter transverse to the lumen 158. A wire 164 is threaded through opening 160, through the lumen 158 and exits the delivery catheter at opening 162. The wire is sufficiently long that the ends 166 and 168 of the wire extend beyond the outer wall 152 of the delivery catheter 150.
The wire 164 may be formed from copper, stainless steel, or other suitable biocompatible metals or metal alloys. The wire 164 may be a round wire having a diameter from about 0.001 to 0.006 inches. In one embodiment, the round wire is about 0.005 inches in diameter. Alternatively, the wire may be a flat wire and have a thickness of about 0.0001 to 0.0005 inches. In one embodiment, the thickness of the flat wire is about 0.0005 inches.
A loop-shaped frame 170 is formed at the distal end of the delivery catheter by pulling the wire 164 through the distal end 156 of the delivery catheter 150 as shown in
As shown in
Subsequently, a wire 186 is wrapped around the sponge-like material 184 and the loop-shaped frame 170 as shown in
While the fallopian tube member 192 may be formed around a guide wire catheter as previously described, it will be appreciated by those of ordinary skill in the art that the fallopian tube member may be formed around a rolling member as described above with respect to the hemostatic member, and then placed over the guide wire catheter prior to insertion of the member.
One skilled in the art will realize that the fallopian tube member may be deployed in the fallopian tube by numerous other methods well known in the art. For example, the fallopian tube member 192 may be loaded inside a delivery catheter and deployed in the fallopian tube by pushing the member out of the delivery catheter with the coaxial guide wire catheter. Alternatively, the fallopian tube member may be deployed using fiberoptic scope or hysteroscope.
The advantages of the fallopian tube closure device of the present invention are numerous. Because the fallopian tube member of the present invention may be positioned without surgery, the patient is less likely to suffer substantial blood loss or post-operative infection. Moreover as no incisions are made the patient experiences less pain and recovers from the procedure more quickly than other surgical sterilization procedures. Finally, the fallopian tube members of the present invention can be inserted in a doctor's office under local anesthetic. As a result, the use of the fallopian tube member of the present invention provides a less costly option for sterilization than procedures which require hospitalization.
Illustrative embodiments of the present invention have been described in considerable detail for the purpose of disclosing a practical, operative structure whereby the invention may be practiced advantageously. The designs described herein are intended to be exemplary only. The novel characteristics of the invention may be incorporated in other structural forms without departing from the spirit and scope of the invention. The invention encompasses embodiments both comprising and consisting of the elements described with reference to the illustrative embodiments. Unless otherwise indicated, all ordinary words and terms used herein shall take their customary meaning as defined in The New Shorter Oxford English Dictionary, 1993 edition. All technical terms shall take on their customary meaning as established by the appropriate technical discipline utilized by those normally skilled in that particular art area. All medical terms shall take their meaning as defined by Stedman's Medical Dictionary, 27th edition.
This application claims priority to U.S. Patent Provisional Application No. 60/307,893, filed on Jul. 26, 2001.
Number | Name | Date | Kind |
---|---|---|---|
3858571 | Rudolph | Jan 1975 | A |
4292972 | Pawelchak et al. | Oct 1981 | A |
4347234 | Wahlig et al. | Aug 1982 | A |
4404970 | Sawyer | Sep 1983 | A |
4412947 | Cioca | Nov 1983 | A |
4512342 | Zaneveld et al. | Apr 1985 | A |
4606337 | Zimmermann et al. | Aug 1986 | A |
4616998 | Wong | Oct 1986 | A |
4705517 | DiPisa, Jr. | Nov 1987 | A |
4852568 | Kensey | Aug 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4948540 | Nigam | Aug 1990 | A |
4981465 | Ballan et al. | Jan 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5192302 | Kensey et al. | Mar 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5224493 | Sawan et al. | Jul 1993 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5310407 | Casale | May 1994 | A |
5330445 | Haaga | Jul 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5350583 | Yoshizato et al. | Sep 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5382261 | Palmaz | Jan 1995 | A |
5383886 | Kensey et al. | Jan 1995 | A |
5391183 | Janzen et al. | Feb 1995 | A |
RE34886 | Irie | Mar 1995 | E |
5437631 | Janzen | Aug 1995 | A |
5441517 | Kensey et al. | Aug 1995 | A |
5449375 | Vidal et al. | Sep 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5514158 | Kanesaka | May 1996 | A |
5522840 | Krajicek | Jun 1996 | A |
5531759 | Kensey et al. | Jul 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5571181 | Li | Nov 1996 | A |
5584827 | Korteweg et al. | Dec 1996 | A |
5591204 | Janzen et al. | Jan 1997 | A |
5643317 | Pavcnik et al. | Jul 1997 | A |
5656036 | Palmaz | Aug 1997 | A |
5656492 | Glowacki et al. | Aug 1997 | A |
5665114 | Weadock et al. | Sep 1997 | A |
5676689 | Kensey et al. | Oct 1997 | A |
5681334 | Evans et al. | Oct 1997 | A |
5707393 | Kensey et al. | Jan 1998 | A |
5709934 | Bell et al. | Jan 1998 | A |
5716375 | Fowler | Feb 1998 | A |
5725498 | Janzen et al. | Mar 1998 | A |
5741223 | Janzen et al. | Apr 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5830130 | Janzen et al. | Nov 1998 | A |
5861004 | Kensey et al. | Jan 1999 | A |
5916265 | Hu | Jun 1999 | A |
5935147 | Kensey et al. | Aug 1999 | A |
5947997 | Pavcnik et al. | Sep 1999 | A |
5948425 | Janzen et al. | Sep 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6045569 | Kensey et al. | Apr 2000 | A |
6090130 | Nash et al. | Jul 2000 | A |
6090996 | Li | Jul 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6096080 | Nicholson et al. | Aug 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6179863 | Kensey et al. | Jan 2001 | B1 |
6183496 | Urbanski | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6200336 | Pavcnik et al. | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6206931 | Cook et al. | Mar 2001 | B1 |
6245090 | Gilson et al. | Jun 2001 | B1 |
6245527 | Busfield et al. | Jun 2001 | B1 |
6261309 | Urbanski | Jul 2001 | B1 |
6277140 | Ginn et al. | Aug 2001 | B2 |
6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6358284 | Fearnot et al. | Mar 2002 | B1 |
6432116 | Callister et al. | Aug 2002 | B1 |
6482179 | Chu et al. | Nov 2002 | B1 |
6540735 | Ashby et al. | Apr 2003 | B1 |
6569081 | Nielsen et al. | May 2003 | B1 |
7153324 | Case et al. | Dec 2006 | B2 |
7166133 | Evans et al. | Jan 2007 | B2 |
7175652 | Cook et al. | Feb 2007 | B2 |
20010041900 | Callister et al. | Nov 2001 | A1 |
20040087998 | Lee et al. | May 2004 | A1 |
20050013844 | Hadlock et al. | Jan 2005 | A1 |
20050049626 | Burgard | Mar 2005 | A1 |
Number | Date | Country |
---|---|---|
1 182 973 | Dec 2004 | EP |
2522959 | Sep 1983 | FR |
2180529 | Mar 2002 | RU |
1673130 | Aug 1991 | SU |
1690737 | Nov 1991 | SU |
1718837 | Mar 1992 | SU |
9206639 | Apr 1992 | WO |
WO 9426175 | Nov 1994 | WO |
WO 8700062 | Jan 1997 | WO |
WO 9719643 | Jun 1997 | WO |
WO 9822158 | May 1998 | WO |
WO 9825545 | Jun 1998 | WO |
WO 9956692 | Nov 1999 | WO |
0013624 | Mar 2000 | WO |
WO 0032112 | Jun 2000 | WO |
WO 0032250 | Jun 2000 | WO |
WO 0032253 | Jun 2000 | WO |
0072759 | Dec 2000 | WO |
WO 0072759 | Dec 2000 | WO |
WO 0074576 | Dec 2000 | WO |
WO 0145765 | Jun 2001 | WO |
WO 0145765 | Jun 2001 | WO |
WO 0145765 | Jun 2001 | WO |
WO 2001045765 | Jun 2001 | WO |
WO 2005020823 | Mar 2005 | WO |
WO 2005030035 | Apr 2005 | WO |
WO 2005070302 | Aug 2005 | WO |
WO 2006119256 | Nov 2006 | WO |
WO 2007002260 | Jan 2007 | WO |
WO 2007011443 | Jan 2007 | WO |
WO 2007064819 | Jun 2007 | WO |
WO 2007090150 | Aug 2007 | WO |
WO 2007090155 | Aug 2007 | WO |
Entry |
---|
Endoluminal Stenting; Chapter 45, Kenneth R. Kensey; Chapter 46, Artur M Spokojny and Timothy A. Sanborn; and Chapter 48, ,Nicholas N. Kipshidze, Joseph B. Horn, Victor Nikolaychik and John E. Baker; Edited by Ulrich Sigwart; W.B. Saundersl 1996. |
Usefulness of Collagen Plugging with VasoSeal® after PTCA as Compared to Manual Compression with Identical Sheath Dwell Times; Sigmund Silber, MD, Aina Björvik, Holger Mühling, MD, Andreas Rösch, MD; Cathet. Cardiovasc. Diagn. 43: 421-427, 1998. |
Arterial Puncture Site Management; Stephen T. Kee, MD; Applied Radiology, pp. 7-12, Jul. 12, 2000. |
Information from Vascular Solutions web site (www.vascularsolutions.com) on Duett sealing device; two pages, 2001. |
Information from Vasoseal web site (www.vasoseal.com) on VasoSeal ES™, three pages, 2001. |
Information from Vasoseal web site (www.vasoseal.com) on VasoSeal ® VHD, three pages, 2001. |
Information from web site (www.pbm.ct.utwente.nl/dopdrachten/wonder.htm) on Nerve Regeneration, three pages, 2001. |
Pamphlet on Peripheral Vascular Disease; Datascope Collagen Products; VasoSeal; four pages, unknown date. |
U.S. Appl. No. 11/766,606, filed Jun. 21, 2007, Fistula Grafts and Related Methods and System Useful for Treating Gastrointestinal Fistulae. |
Heeschen, C., et al. “Nicotine Stimulates Angiogenesis and Promotes Tumor Growth and Atherosclerosis”. Nature Medicine, vol. 7., No. 7, Jul. 2001. pp. 833-839. |
Himpson, Rebecca C., et al. “Histological evidence for enhanced anal fistula repair using autologous fibroblasts in a dermal collagen matrix”. Comparative Clinical Pathology, Apr. 2006, vol. 16, No. 1. |
Johnson, C., et al. “Matrix Metalloproteinase-9 is Required for Adequate Angiogenic Revascularization of Ischemic Tissues: Potential Role in Capillary Branching”. Circulation Research, vol. 94. (2004) pp. 262-268. |
Khairy, G. E. A., et al. “Percutaneous obliteration of duodenal fistula”. J.R. Coll. Surg. Edinb., 45, Oct. 2000, 342-344. |
Lisle, David A., et al. “Percutaneous Gelfoam Embolication of Chronic Enterocutaneous Fistulas: Report of Three Cases”. Diseases of the Colon & Rectum, vol. 50, No. 2, Dec. 2006. |
Maluf-Filho, F. et al. “Endoscopic Treatment of Esophagogastric Fistulae with an Acellular Matrix”. Gastrointestinal Endoscopy, Elsevier, NL, vol. 59, No. 5, Apr. 2004, p. 151, XP004854594 abstract. |
Miklos, J. R., et al. “Rectovaginal Fistula Repair Utilizing a Cadaveric Dermal Allograft”. International Urogynecology Journal, 1999, vol. 10, No. 6, pp. 405-406. |
Moore, Robert D., et al. “Rectovaginal Fistula Repair Using a Porcine Dermal Graft”. Obstetrics & Gynecology, 2004, 104, 1165-1167. |
Schultz, David J., et al. “Porcine Small instestine Submucosa as a Treatment for Enterocutaneous Fistulas”. Journal of American College of Surgeons, 2002, vol. 194, No. 4, Apr. 2002, pp. 541-543. |
Schwesinger, Wayne H., “Management of Persistent Fistula After Gastrectomy” on-line question (www.medscape.com), posted on May 14, 2002. |
Shaker MA, Hindy AM, Mounir RM, Geaisa KM. Egypt Dent J. Jul. 1995; 41(3): 1237-42. |
Shah, A. M., et al. “Bronchoscopic closure of bronchopleural fistula using gelfoam” abstract. Journal of Association of Physicians of India, 2004, vol. 52, noJUIN, pp. 508-509. |
Sheiman, Robert G., et al. “Percutaneous Treatment of a Pancreatic Fistula after Pancreaticoduodenectomy”. J Vasc Interv Radiol, 2001, vol. 12, No. 4, pp. 524-526. |
Shelton, Andrew A., et al. Transperineal Repair of Persistent Rectovaginal Fistulas Using an Acellular Cadaveric Dermal Grant (AlloDerm®). Diseases of the Colon & Rectum, Sep. 2006, vol. 49, No. 9. |
Wilson Gunn on behalf of unnamed party, Letter to the European Patent Office, Jan. 30, 2007, pp. 1-4. |
Number | Date | Country | |
---|---|---|---|
20030051735 A1 | Mar 2003 | US |
Number | Date | Country | |
---|---|---|---|
60307893 | Jul 2001 | US |